Interleukin 17 (IL-17) is critical in the pathogenesis of inflammatory and autoimmune diseases. Here we report that Act1, the key adaptor for the IL-17 receptor (IL-7R), formed a complex with the inducible kinase IKKi after stimulation with IL-17. Through the use of IKKi-deficient mice, we found that IKKi was required for IL-17-induced expression of genes encoding inflammatory molecules in primary airway epithelial cells, neutrophilia and pulmonary inflammation. IKKi deficiency abolished IL-17-induced formation of the complex of Act1 and the adaptors TRAF2 and TRAF5, activation of mitogen-activated protein kinases (MAPKs) and mRNA stability, whereas the Act1-TRAF6-transcription factor NF-kB axis was retained. IKKi was required for IL-17-induced phosphorylation of Act1 on Ser311, adjacent to a putative TRAF-binding motif. Substitution of the serine at position 311 with alanine impaired the IL-17-mediated Act1-TRAF2-TRAF5 interaction and gene expression. Thus, IKKi is a kinase newly identified as modulating IL-17 signaling through its effect on Act1 phosphorylation and consequent function.
The T H 17 inflammatory helper T cell population, which is distinct from the classical T helper type 1 (T H 1) and T H 2 subsets, has provided important understanding about T cell-mediated immunity. Interleukin 17 (IL-17; also known as IL-17A), a key proinflammatory cytokine produced mainly by the T H 17 cell lineage, is required for host defense against extracellular microorganisms and contributes to the development and pathogenesis of inflammatory and autoimmune diseases [1] [2] [3] [4] [5] [6] [7] [8] . IL-17 concentrations are higher in many inflammatory conditions, including multiple sclerosis, rheumatoid arthritis and psoriasis. Higher IL-17 concentrations are also present in the lungs and blood of patients with allergic asthma and are linked to the severity of asthma [9] [10] [11] . The main function of IL-17A is to coordinate local tissue inflammation via the upregulation of proinflammatory and neutrophil-mobilizing cytokines and chemokines, which include IL-6, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor (TNF), IL-1, CXCL1 (KC), CCL2 (MCP-1), CXCL2 (MIP-2), CCL7 (MCP-3) and CCL20 (MIP-3A). Deficiency in IL-17 leads to diminished antigen-specific T cell-mediated immune responses, including allergen-induced pulmonary inflammation and airway hyper-responsiveness 5, 12 . Although studies have begun to elucidate some aspects of IL-17-inititated signal transduction [13] [14] [15] [16] [17] [18] [19] , precise molecular definition of the mechanisms through which IL-17 couples with multiple endpoints remain unclear. The identification of intermediate signaling components and elucidation of their mechanisms of action are crucial for the development of new therapeutic strategies to attenuate this major proinflammatory pathway.
IL-17 signals through a heteromeric receptor complex composed of two receptor chains: IL-17RA and IL-17RC 20, 21 . The adaptor Act1 has been identified as an essential component in the IL-17 signaling pathway and is required for IL-17-dependent immune responses 13, 18, 20 . IL-17RA, IL-17RC and Act1 are all members of a protein family defined by a conserved SEFIR domain that is responsible for the homotypical interaction between the receptor complex and Act1 (ref. 22) . In a mouse model of allergic pulmonary inflammation, T H 2 responses and lung inflammation in Act1-deficient mice have been shown to be much lower than those in their wild-type littermates (control mice). Notably, Act1 deficiency in epithelial cells results in less IL-17-induced pulmonary neutrophilia in the airway, which indicates an essential role for epithelium-derived Act1 in IL-17-mediated pulmonary inflammation 23 .
Act1 has two TRAF-binding sites: a helix-loop-helix domain at the amino terminus, and a coiled-coil domain, which contains the SEFIR domain, at the carboxyl terminus 24 . After stimulation with IL-17, Act1 is recruited to IL-17R through SEFIR domain-SEFIR domain interaction, followed by recruitment of the kinase TAK1 and the E3 ubiquitin ligase TRAF6 that mediate downstream signaling events 18, 25 .
Act1 is a U-box E3 ubiquitin ligase whose activity is essential for IL-17-mediated signaling pathways (including activation of the transcription factor NF-κB and the kinases Jnk, p38 and Erk) and for the expression of genes encoding inflammatory molecules (such as the chemokine CXCL1, colony-stimulating factor 2 and IL-6) in mammalian cells 26 . Through the use of the Ubc13-Uev1A E2 complex, Act1 mediates Lys63-linked ubiquitination of TRAF6, an important signaling component of IL-17-mediated NF-κB activation. However, TRAF6 is not required for IL-17-induced activation of Erk and p38, which indicates the existence of an IL-17-induced and Act1-mediated but TRAF6-independent pathway. In addition to inducing gene transcription, stimulation with IL-17 also prolongs the half-life of chemokine mRNA, which is also mediated by an Act1-dependent but TRAF6-independent pathway 14 .
One important question is how Act1 is activated and regulated after stimulation with IL-17 to mediate the various downstream signaling pathways. In this study, we found that after stimulation with IL-17, the kinase IKKi (inducible inhibitor of NF-κB (IκB) kinase; also known as IKKε) 27, 28 formed a complex with Act1 and mediated IL-17-induced phosphorylation of Act1, which was critical for the modulation of Act1-dependent signaling. Furthermore, through the use of IKKideficient mice, we found that IKKi was required for IL-17-induced expression of genes encoding inflammatory molecules (Cxcl1, Cxcl2, Tnf, Il6 and Csf3) in primary airway epithelial cells, neutrophilia and pulmonary inflammation, which indicates that IKKi is a key component of the inflammatory response to IL-17. The identification of IKKi as a critical upstream kinase of Act1 in the IL-17 pathway will facilitate the development of new anti-inflammatory therapies to attenuate IL-17-dependent autoimmune inflammatory diseases.
RESULTS

IKKi forms a complex with Act1 after stimulation with IL-17
To understand how Act1 is activated and linked to downstream signaling factors after stimulation with IL-17, we searched for additional proteins that immunoprecipitated together with tagged Act1 used for the reconstitution of Act1-deficient primary mouse embryonic fibroblasts (MEFs). As IL-17R and Toll-like receptor-IL-1 receptor mediate many similar downstream signaling events, we assessed a set of candidate signaling components linked to Toll-like receptor-IL-1 receptor pathways for their interaction with Act1. Through this search, we found that Act1 (~72 kDa) formed a complex with IKKi in response to stimulation with IL-17 (Fig. 1a) . IKKi has an important role in the innate immune response by activating the transcription factors IRF3 and IRF7 during viral infection [29] [30] [31] [32] . IL-17 induced a form of Act1 with greater apparent molecule mass, which 'shifted down' to its normal size after treatment with phosphatase (Fig. 1b) ; this suggested that Act1 is phosphorylated after stimulation with IL-17. Notably, when we used antibody to IKKi (anti-IKKi) for immunoprecipitation of lysates of untreated and IL-17-treated MEFs, we detected only the modified form of Act1 in the immune complex of IKKi (Fig. 1c) , which indicated that IKKi interacted mainly with this form of Act1.
IKKi in IL-17-induced inflammatory gene expression
The finding that IKKi formed a complex with Act1 in response to stimulation with IL-17 suggested that IKKi may have a role in IL-17-mediated signaling pathways. We first determined whether IKKi is required for IL-17-induced expression of genes encoding inflammatory molecules. For this study we used differentiated mouse primary airway epithelial cells cultured at the air-liquid interface, as deficiency in Act1 in epithelial cells results in lower IL-17-induced expression of genes encoding inflammatory molecules and neutrophilia 23 . It is well documented that IL-17A and IL-17F can induce the expression of genes encoding proinflammatory molecules both alone and in synergy with TNF. To determine if IKKi is required for the IL-17 signaling pathway, we analyzed the expression of several genes encoding proinflammatory molecules (Cxcl1, Cxcl2, Tnf, Il6 and Csf3) by realtime PCR after treatment of IKKi-deficient and wild-type (control) airway epithelial cells with TNF, IL-17A or IL-17F alone, or TNF plus either IL-17A or IL-17F (Fig. 2a) . TNF-stimulated expression of Cxcl1, Cxcl2, Tnf, Il6 and Csf3 was not different in IKKi-deficient and wild-type cells, which indicated that IKKi is not involved in mediating signaling pathways via TNF. In contrast, the expression of Cxcl1, Cxcl2, Tnf, Il6 and Csf3 induced by IL-17A and IL-17F alone or in synergy with TNF was substantially attenuated in IKKi-deficient airway epithelial cells (Fig. 2a) , which demonstrated that IKKi is important for the response to IL-17.
To study the direct effect of IKKi on IL-17-induced signaling events, we prepared airway epithelial cells from wild-type and IKKideficient mice and assessed the ability of IL-17 to stimulate the activation of mitogen-activated protein kinases (MAPKs). IL-17-induced activation of p38 was abolished in airway epithelial cells from IKKideficient mice, in contrast to the p38 activation in wild-type control cells, whereas Erk signaling was much lower and Jnk signaling was somewhat lower in IKKi-deficient cells (Fig. 2b) . In contrast, IL-17 induced similar extent of IκB phosphorylation and NF-κB activation (phosphorylation of the NF-κB subunit p65) in wild-type and IKKi-deficient cells. Thus, whereas IL-17-mediated production of cytokines and chemokines was abolished in IKKi-deficient cells, IKKi deficiency resulted in much less IL-17-induced MAPK activation. As a control, we found that IKKi deficiency did not have any effect on TNF-induced signaling events (Fig. 2b) , which indicated the specificity of IKKi in IL-17 signaling. A r t i c l e s
IL-17-mediated neutrophilia requires IKKi
The main function of IL-17 is to coordinate local tissue inflammation via the upregulation of proinflammatory and neutrophil-mobilizing cytokines and chemokines. Epithelium-derived Act1 is required for IL-17-mediated neutrophilia and allergic pulmonary inflammation 23 .
As IKKi formed a complex with Act1 after stimulation with IL-17 and had an important role in IL-17-mediated expression of genes encoding inflammatory molecules (Fig. 2) , we next examined the in vivo effect of IKKi deficiency on IL-17-induced pulmonary inflammation. We treated wild-type and IKKi-deficient mice on the C57BL/6 background with recombinant IL-17 via intranasal injection. We killed the mice 24 h after challenge and analyzed the cells in the bronchoalveolar lavage (BAL) fluid and lung inflammation. There were significantly fewer infiltrating cells, especially neutrophils, in IKKi-deficient mice than in wild-type mice (Fig. 3a) . Histological analysis of lung tissue showed less lung inflammation in IKKi-deficient mice (Fig. 3b) . The diminished inflammatory phenotype correlated with the lower abundance of CXCL1 (a potent neutrophil chemokine) in the BAL fluid and lungs (Fig. 3c,d) . Furthermore, IL-17-induced expression of Cxcl1, Cxcl2, Tnf, Il6 and Csf3 was abolished in IKKi-deficient lung tissue, in contrast to their expression in wild-type lung tissue (Fig. 3d) . Together these results indicate that IKKi is required for IL-17-mediated neutrophilia and pulmonary inflammation.
IKKi mediates the stabilization of chemokine mRNA IL-17 has been shown to modulate gene expression at both the transcriptional and post-transcriptional level 14, 18 . Because NF-κB activation was not affected in IKKi-deficient cells, we reasoned that IKKi might be necessary for the ability of IL-17 to promote the stabilization of chemokine mRNA, as reported before 14 . We first treated wild-type and IKK-deficient MEFs for 0.5 h with TNF to promote transcription of Cxcl1, then treated them for 0.5-4 h with actinomycin D (to block transcription) along with IL-17 (for mRNA stabilization). Although CXCL1 mRNA was induced to similar extent in wild-type and IKKi-deficient MEFs after the initial treatment with TNF, the mRNA decayed more rapidly and reached a lower plateau in IKKi-deficient MEFs than in wild-type MEFs (Fig. 4a) . These results indicated that IKKi is necessary for IL-17-mediated stabilization of CXCL1 mRNA.
To explore this potential regulatory mechanism in more detail, we examined the effect of IKKi kinase activity on mRNA stabilization through the use of the Tet-Off expression system 33 . The reporter plasmid (pTRE2 CXCL1∆4) includes the 5′ untranslated region and coding region, as well as the IL-17-sensitive portion of the 3′ untranslated region, of CXCL1 mRNA under control of a tetracycline-response element (TRE). We transiently cotransfected HeLa human cervical cancer cells stably expressing the tetracycline-controlled transactivator with this reporter plasmid (pTRE2 CXCL1∆4) along with wild-type or kinase-inactive IKKi (with substitution of alanine for the lysine at position 38 (IKKi(K38A)). In the absence of tetracycline or its analog doxycycline, the tetracycline transactivator drives considerable transcription of the transgene encoding CXCL1. After the addition of doxycycline to the culture medium, transcription is abolished, which allowed us to measure the abundance of residual CXCL1 mRNA and GAPDH mRNA (encoding glyceraldehyde phosphate dehydrogenase) over 0, 30, 60 and 90 min by RNA-hybridization analysis. Wild-type IKKi promoted the stabilization of CXCL1 mRNA, but the kinase-inactive IKKi mutant did not (Fig. 4b) . These results indicated that overexpression of IKKi was sufficient to mediate the stabilization of CXCL1 mRNA and that the kinase activity of IKKi was required for this process.
As it has been shown that overexpression of Act1 can mediate the stabilization of CXCL1 mRNA, we then examined the effect of the kinase activity of IKKi on Act1-mediated mRNA stabilization through the use of the Tet-Off expression system as described above 33 . We transiently cotransfected HeLa Tet-Off cells with pTRE2 CXCL1∆4 along with Act1 and either wild-type IKKi or the kinase-inactive IKKi mutant. We treated the transfected cells with doxycycline to allow reporter CXCL1 mRNA to decay for 0, 30, 60 and 90 min and assessed remaining reporter CXCL1 mRNA and GAPDH mRNA as described above. The kinase-inactive IKKi mutant inhibited the ability of Act1 to mediate the stabilization of CXCL1 mRNA (Fig. 4c) . These results suggested that the kinase-inactive IKKi mutant probably functioned as a dominant negative mutant that inhibited signals downstream of Act1 that coupled with the stabilization of CXCL1 mRNA.
IKKi mediates the phosphorylation of Act1
Our results indicated that IKKi has an essential role in IL-17-mediated gene expression and in vivo inflammatory responses. We investigated how IKKi participates in IL-17 signaling at the molecular level. IL-17 induced the phosphorylation of Act1, and we detected only the modified form of Act1 in immune complexes with IKKi ( Fig. 1) , which suggested that IKKi may directly modulate Act1. To determine the role of IKKi in IL-17-induced phosphorylation of Act1, we examined Act1 modification in untreated and IL-17-treated airway epithelial cells from wild-type and IKKi-deficient mice. Notably, Act1 phosphorylation induced by IL-17 (IL-17A or IL-17F) was much lower in IKKi-deficient airway epithelial cells than in wild-type control cells (Fig. 5a) . To determine whether the kinase activity of IKKi is important for Act1 phosphorylation, we overexpressed wild-type IKKi and kinase-inactive IKKi (with the K38A substitution) in human embryonic kidney 293 cells, followed by immunoblot analysis of Act1. Wild-type IKKi induced a form of Act1 with slower migration, which shifted down to its normal size after phosphatase treatment, but kinase-inactive IKKi did not induce the slower Act1 (Fig. 5b) ; this indicated that the kinase activity of IKKi is required for Act1 phosphorylation. We then determined whether IKKi directly phosphorylates Act1 in vitro. We assessed by in vitro kinase assay Act1 immunoprecipitated from wild-type MEFs with or without purified recombinant IKKi protein. We used immunoprecipitates from Act1-deficient MEFs as a negative control. Notably, we observed that recombinant IKKi was able to effectively phosphorylate Act1 in vitro (Fig. 5c) , which indicated the importance of IKKi in Act1 phosphorylation. Although IKKi mediated Act1 phosphorylation, it was also necessary to examine IL-17-mediated activation of IKKi. We immunoprecipitated IKKi from lysates of MEFs and primary kidney epithelial cells left untreated or treated with IL-17, then analyzed the results by in vitro kinase assay. We detected more IKKi phosphorylation in lysates of each cell type at 15 min after stimulation with IL-17 ( Fig. 5d) . Notably, IL-17-induced autophosphorylation of IKKi was much lower in Act1-deficient kidney epithelial cells. These results indicate that stimulation with IL-17 probably leads to IKKi activation in an Act1-dependent manner. However, studies have shown the IKKi expression can be induced by extracellular stimuli, including lipopolysaccharide 28 . Therefore, we determined whether IL-17 also upregulates IKKi expression. Stimulation with IL-17 indeed induced moderate amounts (Fig. 5e) . Together our results show that stimulation with IL-17 affects both the expression and activation of IKKi.
IL-17 induces phosphorylation of Act1 at Ser311
We next attempted to identify the IL-17-induced IKKi-mediated phosphorylation sites of Act1 by tandem mass spectrometry. We reconstituted Act1-deficient MEFs with mouse Act1 and stimulated them for 30 min with IL-17, followed by immunoprecipitation of mouse Act1 and SDS-PAGE. We excised bands corresponding to Act1, including regions covering modified forms of Act1 (~72 kDa), and digested them in-gel with trypsin. We then analyzed the digestion products by electrospray ionization-nano-liquid chromatographyFourier transform mass spectrometry. We confirmed that the main protein was Act1, with sequence coverage of 60%. An Act1 peptide of amino acids 305-322 (sequence, VILNDSSPQDEERPAQR) was phosphorylated on Ser311; notably, this peptide species was present in IL-17-treated samples but not in untreated samples. We obtained the same results by tandem mass spectrometry of biological triplicates. We determined the mass spectra of this peptide in both the modified form (m/z (mass/charge) = 721.3311; Fig. 6a ) and unmodified form (m/z = 694.6769; Fig. 6b ). These peptides were triply charged; the mass difference of the two precursor ions was therefore 79. Moreover, we precisely located Ser311 (human Ser328) from the detection of product ions y 11 2+ and y 12 2+ (doubly charged). In the modified and unmodified peptides, the m/z of y 11 2+ was 677.3 and 677.1 (1-Da mass tolerance for product ions), respectively, whereas the m/z of y 12 2+ was 760.8 by mass spectrometry of the modified peptide and 720.8 by mass spectrometry the unmodified peptide. The mass difference of these two product ions was 80 Da (calculated as (760.8 − 720.8) × 2). Other y ions after y 12 (y 13 , y 14 , y 15 and y 16 ) all had a mass shift of 80 Da by modified mass spectrometry relative to the mass of their counterparts by unmodified mass spectrometry.
The evidence that a phosphate group was attached to y 12 ions but not to y 11 ions proved that Ser311, the only amino acid that was different in the two species, was the phosphorylated site.
We then determined whether IKKi phosphorylated Act1 at Ser311 in vitro. We immunoprecipitated Act1 from wild-type MEFs with or without purified recombinant IKKi protein and analyzed it by in vitro kinase assay. The peptide of amino acids 305-322 with phosphorylated Ser311 (noted above) was present in IKKi-treated samples but not in untreated samples (data not shown). To evaluate the biological consequence of Ser311-phosphorylation event, we generated an Act1 point mutant with substitution of alanine for the serine at position 311 (Act1(S311A)). There was less IL-17-induced modification (phosphorylation) of Act1 in Act1-deficient MEFs reconstituted with Act1(S311A) than in with those reconstituted with wild-type Act1 (Fig. 6c) . Furthermore, there was also less IKKi-mediated modification of Act1 in 293 cells transfected with constructs encoding IKKi plus Act1(S311A) than in those transfected with constructs encoding IKKi plus wild-type Act1. Together these results suggest that Ser311 is indeed a site that contributes to IL-17-induced, IKKi-mediated phosphorylation of Act1. Furthermore, IL-17-induced expression of CXCL1 mRNA and IL-6 mRNA was lower in Act1-deficient MEFs reconstituted with Act1(S311A) than in those reconstituted with wild-type Act1 (Fig. 6d) . Consistent with the role of IKKi in IL-17-induced MAPK activation and mRNA stabilization, there was less IL-17-induced activation of Erk and p38 as well as stabilization of CXCL1 mRNA in Act1-deficient MEFs reconstituted with Act1(S311A) (Fig. 6e,f) , which demonstrated that IKKi-mediated Act1 phosphorylation is important for IL-17 signaling. Although the S311A substitution did not affect IL-17-induced activation of NF-κB ( Fig. 6e and data not shown) , IL-17-induced phosphorylation of IκB was prolonged in MEFs relative to that in epithelial cells 26 (Fig. 2b) .
IKKi regulates the interaction of Act1 with TRAF proteins
Act1 forms a complex with TRAF6 after stimulation with IL-17 (refs. 14,22), which is required for IL-17-mediated activation of NF-κB but not for IL-17-induced, Act1-mediated activation of Erk and p38 or stabilization of mRNA 14 , which demonstrates the existence of IL-17-Act1-mediated but TRAF6-independent pathways. 
A r t i c l e s
The finding that IKKi deficiency abolished IL-17-induced MAPK activation and mRNA stabilization, but not NF-κB activation, suggested that IKKi-mediated signaling is TRAF6 independent. Notably, TRAF2 and TRAF5 are required for IL-17-induced stabilization of mRNA, which suggests that TRAF2 and TRAF5 may function downstream of IKKi to mediate IL-17-Act1-induced mRNA stabilization. The serine residue of Act1 targeted by IKKi is located adjacent to a putative TRAF-interacting consensus motif (P/S/T/AXQ/E-acidic/polar, where 'P/S/T/A' is proline, serine, threonine or alanine; 'X' is any amino acid; 'Q/E' is glutamine or glutamic acid; and '-acidic/polar' is any acidic or polar amino acid; mouse Act1 residues 310-317 and human Act1 residues 327-334). Therefore, we hypothesized that phosphorylation of this serine residue by IKKi might modulate the interaction between Act1 and various TRAF proteins. After stimulation with IL-17, Act1 formed complexes with various modified (probably ubiquitinated) forms of TRAF2, TRAF5 and TRAF6 (refs. 18,26; Fig. 7a ). Act1 mediates TRAF6 ubiquitination after stimulation with IL-17, which is required for IL-17-induced activation of NF-κB 26 . The observed modification of TRAF2, TRAF5 and TRAF6 was probably due to ubiquitination (Fig. 7b) . Additional studies are needed to further define the IL-17-induced modification of TRAF2 and TRAF5. Notably, we found that IKKi deficiency abolished the IL-17-induced interaction of Act1 with TRAF2 and TRAF5 but allowed the Act1-TRAF6 interaction to be retained (Fig. 7a) . Furthermore, there was much less IL-17-induced interaction of Act1 with TRAF2 and TRAF5 in Act1-deficient MEFs reconstituted with Act1(S311A), but there was not less Act1-TRAF6 interaction (Fig. 7b) . Together these results indicate that IKKi and phosphorylation of Act1 at Ser311 influence the specificity of interactions between Act1 and various TRAF proteins.
Computational modeling of Act1-TRAF interactions
As noted above, Act1 Ser311, which is targeted by IKKi, is located adjacent to a TRAF-interacting consensus motif (mouse Act1 residues 310-317 and human Act1 residues 327-334). To obtain insight into how phosphorylation of this serine residue might affect the interaction of Act1 with TRAF proteins, we computationally docked a peptide of human Act1 amino acids 327-334 onto crystal structures of TRAF domains from TRAF6 and TRAF2, and onto a homology model of the TRAF domain of TRAF5, which has high similarity to the sequence of TRAF2. We were guided by structures of these TRAF domains bound to TRAF-interacting motifs from a variety of ligands, including CD40 (TRAF6 ligand) and TNFR2 (TRAF2 ligand) [34] [35] [36] . In these ligands, the TRAF-interacting motifs make a small number of backbone-backbone interactions with strand β7 of the TRAF domains but lie mainly across one of the sheets of the TRAF-domain β-sandwich fold. In both TRAF6 and TRAF2, the residue at the so-called P −2 position of the ligand motif (typically proline, serine, threonine or alanine) makes close contact with a hydrophobic pocket on one side of the interacting surface (residues from β-strands β6 and β7), whereas the residue at position P o (typically occupied by glutamine or glutamic A r t i c l e s acid) and subsequent acidic and/or polar residues interact with basic and polar side chains from the other side of the surface (residues from strands β3 and β4).
We were able to dock the human Act1 TRAF-interacting sequence (PSPWDQEE; corresponding to mouse SSPQDQEE) onto TRAF6, TRAF5 and TRAF2 in configurations resembling those of structurally characterized TRAF ligands. Because the Act1 sequence contains multiple residues potentially compatible with positions P −2 and P 0 , the Act1 sequence may dock onto TRAF6 and TRAF5-TRAF2 in different registers. In our best models of the Act1-TRAF6 interaction, human Act1 Trp330 occupied the P 0 position and made favorable hydrophobic interactions with nonpolar residues that formed a bulge on the TRAF6 surface (Fig. 7c) . In other TRAF6 ligands, position P 0 is occupied by a glutamate side chain 36 , which made similar hydrophobic contacts, whereas its carboxylate group was stabilized by hydrogen bonding to TRAF backbone amides (Fig. 7c,d ). In addition, the equivalent residue in mouse Act1 is a glutamine (Gln313), which presumably interacts with TRAF6 in a manner similar to its interaction with the glutamate residues of other TRAF6 ligands. Human Act1 Ser328 (mouse Act1 Ser311) occupies position P -2 and closely contacted the corresponding hydrophobic pocket. The serine side chain may be partially stabilized by hydrogen bonding to TRAF6 Tyr473, which forms one wall of the pocket. Our modeling suggests that phosphorylation of this serine residue by IKKi may destabilize the binding of Act1 to TRAF6 because the bulky, charged phosphorylated serine would sterically clash with the small P −2 binding pocket.
In contrast, our modeling of the Act1-TRAF5 and Act1-TRAF2 interactions (Fig. 7c,e,f) suggested that position P −2 was filled by human Act1 Pro329 (mouse Act1 Pro312) and position P 0 was occupied by an acidic residue, Asp331 (mouse Act1 Asp314). This binding mode positioned the side chain of the key serine residue at position 328 (mouse Act1 Ser311) so that it protruded away from the TRAF domain surface but was proximal to a basic side chain (human TRAF5 Lys500 or TRAF2 Arg448, which are conserved in their mouse homologs). Phosphorylation of Ser328 (mouse Act1 Ser311) allowed the formation of a salt bridge between the phosphate and the basic residue, which increased the affinity of the Act1 motif for TRAF5 and TRAF2. Our modeling results therefore suggest that phosphorylation of Act1 promotes redistribution from TRAF6 to TRAF5 (and/or TRAF2) in a twofold manner. First, the phosphorylation results in a lower affinity for TRAF6 due to incompatibility between the phosphate group and the P −2 binding pocket. Second, the phosphorylation gives rise to additional favorable electrostatic interactions with the surface of TRAF5 or TRAF2. This interpretation is consistent with our experimental data presented above on the effect of IKKi on the balance of Act1-mediated signaling pathways. DISCUSSION IL-17 is produced mainly by pathogenic T H 17 cells and has been linked to the pathogenesis of many autoimmune inflammatory diseases. Because IL-17 uses a unique receptor, the identification of signaling pathways that couple receptor activation with physiological end points and understanding of their mechanisms of action are crucial for the development of new therapeutic strategies to attenuate this major proinflammatory pathway. We have reported here a previously unknown function for IKKi in IL-17-mediated signaling linked with neutrophilia and pulmonary inflammation. IKKi deficiency abolished IL-17-induced airway inflammation via the impaired expression of proinflammatory and neutrophil-mobilizing cytokines and chemokines. We found that stimulation with IL-17 induced the interaction of IKKi with Act1, which resulted in phosphorylation of Act1; this had a critical effect on a subset of IL-17-induced activities. The identification IKKi as a critical upstream kinase in the IL-17 pathway opens new avenues for the development of novel anti-inflammatory therapies. Although IL-17 induces transcriptional activation of genes encoding inflammatory molecules, it also affects their production at the post-transcriptional level 14 . Many cytokine and chemokine mRNAs are known to have half-lives shortened by mechanisms that depend on sequences located in the 3′ untranslated region. The best characterized instability sequences contain adenine-and uridine-rich elements characterized by the pentamer AUUUA or nonamer UUAUUUAUU 37, 38 . These instability sequences are recognized by RNA-binding proteins such as tristetraprolin, which promote the degradation of mRNA through the recruitment of decapping, deadenylase and exonuclease activities. The sequence motif in the 3′ untranslated region of CXCL1 mRNA that confers IL-17 sensitivity does not contain the AUUUA motif and is not recognized by tristetraprolin 37 . IL-17-sensitive instability has also been shown to be mediated by the arginine-and serine-rich splicing factor SF2 (ASF) 39 . Notably, mRNA-decay mechanisms can be regulated via MAPK-dependent signaling, including signaling by p38, Erk and Jnk [40] [41] [42] [43] . It is notable that in IKKi-deficient cells, IL-17-induced activation of MAPK was much lower but that of NF-κB was not, which might contribute to the inability of IL-17 to stabilize chemokine mRNA in these cells.
In this context, Act1 forms a complex with TRAF6 after stimulation with IL-17 to mediate IL-17-dependent activation of NF-κB but not stabilization of mRNA 14, 26 . Act1 is required for IL-17 induction of immediate-early genes, and Act1 is essential for IL-17-mediated activation of NF-κB 44 . Moreover, we found that TRAF2 and TRAF5 were required for IL-17-induced stabilization of mRNA. The serine residue in Act1 targeted by IKKi is located adjacent to a putative TRAF-interacting consensus motif 26 . Our computational modeling suggested that phosphorylation of Act1 Ser311 modulated its affinity for TRAF6 and TRAF5 (and/or TRAF2), which enabled signaling through these additional TRAF components. These results suggest that IKKi-mediated phosphorylation of Act1 might have a critical effect on the selective interaction of Act1 with various TRAF proteins and on specific Act1-dependent IL-17 signaling pathways. IKKi deficiency and substitution of Act1 Ser 311 indeed abolished IL-17-induced formation of the Act1-TRAF2 or Act1-TRAF5 complex and stabilization of chemokine mRNA, whereas the Act1-TRAF6-NF-κB axis was retained. Therefore, IKKi is an important kinase that controls the bifurcation of TRAF2-and TRAF5-dependent versus TRAF6-dependent signaling pathways through its effect on Act1 phosphorylation, promoting IL-17-induced expression of genes encoding inflammatory molecules at the post-transcriptional level. Notably, the IKKi-mediated phosphorylation of Act1 may affect additional aspects of Act1 and Act1-mediated downstream signaling.
However, it is unlikely that IKKi-mediated phosphorylation of Act1 is required for the E3 ligase activity of Act1 (ref. 26) , as neither deficiency in IKKi nor the S311A substitution of Act1 affected the IL-17-induced activation of NF-κB, which is dependent on the E3 ligase activity of Act1. These findings not only increase the mechanistic understanding of IL-17 signaling but also provide useful information for future cell-based assays in the development and analysis of candidate inhibitors of IKKi.
Although we detected only the modified form of Act1 in the immunocomplex of IKKi, it remains unclear how IKKi is activated after stimulation with IL-17 and is recruited to Act1. It is known that Act1 is recruited to IL-17R through SEFIR domain-SEFIR domain interaction. Notably, the IL-17R SEFIR domain alone was not sufficient to support IL-17-dependent signaling. Instead, an additional sequence located carboxy-terminally to SEFIR was also necessary 15 . Moreover, the extended SEFIR region in IL-17RC is required for interaction with a phosphorylated form of Act1. Consistent with that, we observed that IKKi was able to interact with IL-17R in the absence of Act1 and that the SEFIR domain of IL-17R was not required for this interaction, which suggests that IKKi is possibly recruited to the receptor through sequences carboxy-terminal of the SEFIR domain in the IL-17R (data not shown). However, we found that Act1-deficient cells had less IL-17-induced autophosphorylation of IKKi, which indicated that Act1 is probably still required for IKKi activation in response to stimulation with IL-17. The activated IKKi then in turn phosphorylated Act1. Additional studies are needed to elucidate the details of the molecular mechanism for the activation and recruitment of IKKi to IL-17R-Act1 in response to stimulation with IL-17.
IKKi is an IKK-related kinase. Mass spectrometry analysis showed that IKKi phosphorylated Act1 at Ser311 in vitro, which indicates that IKKi may act as a direct kinase of Act1. The S311A substitution of Act1 impaired IL-17-mediated gene expression and stabilization of CXCL1 mRNA, which demonstrates the importance of IL-17-induced, IKKi-mediated phosphorylation of Act1 in IL-17 signaling. Although IKKi was able to phosphorylate Act1 in vitro, other kinases may also be involved in the phosphorylation of Act1 in response to stimulation with IL-17. Notably, the S311A substitution of Act1 did not completely abrogate IL-17-mediated modification of Act1, which suggests that additional phosphorylation or modification sites are present in Act1. Furthermore, IKKi might also phosphorylate substrates other than Act1 in response to stimulation with IL-17. Together with the kinase TBK1, IKKi has been shown to have an important role in the innate immune response, in which it functions as a kinase for IRF3 and IRF7 signaling pathways during viral infection 29, 31, 32 . We did explore the possible link from IKKi to IRF activation in response to stimulation with IL-17. However, we did not detect any IL-17-induced, IKKimediated activation of IRF signaling pathways (data not shown). This previously unknown function of IKKi in IL-17 signaling indicates that the multifaceted nature of this kinase, whose spatiotemporal regulation and activation are probably crucial for its appropriate functions in various signaling pathways and consequent immune responses.
Another question is whether IKKi also participates in signaling pathways mediated by other IL-17 family members. Act1 is required for signaling and inflammation mediated by IL-25 (IL-17E). IL-25 is the most divergent member of the IL-17 family; it is expressed in mouse T lymphocytes of the CD4 + subset with a T H 2 profile and human innate effector eosinophils and basophils. IL-25 has an important role in the initiation and propagation of the T H 2 immune response. IKKi-deficient mice had much less IL-25-induced infiltration of cells into BAL fluid and lung inflammation than did wild-type mice (K.B. and X.L., data not shown). Therefore, additional studies are needed to investigate how IKKi participates in Act1-dependent signaling induced by other members of the IL-17 family.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
